. Author manuscript; available in PMC: 2014 May 30.

Published in final edited form as: Clin Breast Cancer. 2012 Dec 6;13(2):103–108. doi: 10.1016/j.clbc.2012.11.003

Table 3.

Comparison of Studies Evaluating βIII-Tubulin Expression in Breast Cancer

Study	βIII-Tubulin Assessment Method	Definition of High βIII Expression	Number of Patients	Patient Population	ER⁻Disease	Endpoint	High βIII-Tubulin Correlated With Clinical Outcomes
Bernard-Marty et al²²	IHC clone TUJ1	≥ 50%	34	Metastatic 83%	Not stated	Time to progression	No
Paradiso et al²³	IHC clone SDL 3D10	≥ 50%	70	Metastatic 29%	27%	Clinical response	Yes, associated with paclitaxel resistance
Tommasi et al²⁴	IHC clone SDL 3D10	≥ 50%	92	Advanced	35.5%	Clinical response	Yes, associated with paclitaxel resistance
Hasegawa et al²⁵	mRNA RT-PCR	≥ Median RNA expression level	39	Locally advanced (67%)	56%	Clinical response	Yes, associated with docetaxel resistance
Galmarini et al⁹	IHC clone TUJ1	≥ Median	173	Locally advanced	Not stated	Time to progression	Yes, associated with docetaxel sensitivity
Wang et al (Current Article)	IHC clone TUJ1	≥ Median	44	Operable or locally advanced	55%	Pathologic response	Yes, associated with paclitaxel sensitivity

Abbreviations: ER⁻ = estrogen receptor negative; IHC = immunohistochemical; RT-PCR = reverse transcription polymerase chain reaction.